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Abstract
The discovery of the first microRNA (miRNA) over 20 years ago has ushered in a new era in 
molecular biology. There are now over 2000 miRNAs that have been discovered in humans and it 
is believed that they collectively regulate one third of the genes in the genome. miRNAs have been 
linked to many human diseases and are being pursued as clinical diagnostics and as therapeutic 
targets. This review presents an overview of the miRNA pathway, including biogenesis routes, 
biological roles, and clinical approaches.
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1. miRNAs are small noncoding regulatory RNAs
The first miRNA was discovered over 30 years ago in the nematode Caenorhabditis elegans 
with the identification of the developmental regulator lin-4[1]. Originally believed to be a 
conventional protein coding gene, the Ruvkun and Ambros labs made the startling discovery 
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that lin-4 did not code for a protein but instead coded for a 22 nucleotide regulatory RNA[2, 
3]. They demonstrated that the lin-4 RNA could base pair with the mRNA for another gene 
in the C. elegans developmental network, lin-14, and control the production of the LIN-14 
protein[3]. This discovery would have had limited significance outside of the C. elegans 
research community had a second miRNA, let-7, not been discovered[4]. More importantly, 
let-7 is conserved across many organisms, including humans, suggesting that this class of 
small regulatory RNAs has a more general role in biology[5]. The other stunning 
development, occurring around the same time, was the discovery of the RNAi pathway; 
specifically, the ~21 nucleotide RNA triggers of the silencing machinery[6-9]. These two 
pathways have since been shown to be different arms of the same gene silencing 
pathway[10-12]. Subsequently, many thousands of miRNAs have been discovered in many 
organisms, and there are currently 2588 annotated miRNAs in the human genome[13]. Since 
each miRNA is predicted to regulate the expression of hundreds of target genes, the miRNA 
pathway as a whole is a critical mechanism for gene expression control[14].
2. The canonical miRNA biogenesis pathway
All miRNA families undergo a series of biogenesis steps that convert the primary miRNA 
transcript into the active, ~22 nucleotide mature miRNA (see Figure 1). The mature miRNA 
is loaded into the RNA induced silencing complex (RISC) where it directs the complex to 
target mRNAs, leading to translational repression and target mRNA degradation. This 
section will cover the canonical miRNA biogenesis pathway that is responsible for the 
maturation of most miRNA families. For simplicity we will focus on the mammalian 
enzyme components. Several exceptions to this canonical pathway have been described for 
unique miRNA families, and are discussed in a later section.
2.1. Transcription
miRNA genes are located throughout the genome[15]. Many miRNA genes are noncoding 
genes whose sole transcriptional product is the miRNA. In other cases the miRNA is located 
within an intron or untranslated region (UTR) of a protein coding gene. Figure 2 exemplifies 
a cluster of three miRNAs located within an intron of the protein coding gene MCM7[16, 
17]. The defining feature of all miRNA genes is the stem-loop precursor RNA structure, 
with one (or sometimes both) strands of the stem the source of the mature miRNA[18-20]. 
In the case of MCM7 there are three clustered miRNA stem loops, each leading to a distinct 
mature miRNA with a unique target set[21]. miRNAs are not generally located within 
coding exons, as excision of the miRNA would lead to loss of the protein coding transcript.
Transcription of the miRNA host gene by RNA polymerase II leads to the pri-miRNA, or 
primary miRNA transcript[22, 23]. The pri-miRNA is typically spliced, capped, and 
polyadenylated in a similar manner to protein coding mRNAs[24]. While most miRNA 
promoters have not been characterized in detail, the few examples studied are similar in 
structure to protein coding gene promoters, including control elements and histone 
marks[25-33].
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2.2. Processing by Drosha and Dicer
The pri-miRNA requires two endonuclease processing steps before it becomes a mature, 
active miRNA[34]. The first processing step occurs during or subsequent to transcription of 
the pri-miRNA by the enzyme Drosha[35-38]. The RNA binding protein DGCR8 is 
associated with Drosha and is required for cleavage of the pri-miRNA[39-41]. Drosha 
cleavage releases the stem-loop precursor from flanking pri-miRNA transcript sequences. 
The precursor is exported out of the nucleus in a Ran-GTPase dependent manner by 
Exportin5[42-44]. In the cytoplasm the second processing step occurs. The endonuclease 
Dicer cleaves the loop region of the precursor releasing the mature miRNA[10-12, 45]. Like 
Drosha, Dicer is also associated with an RNA binding protein, in this case TRBP[46-50]. 
The product of the Dicer reaction is a duplex RNA of approximately 21 nucleotides length 
(depending on the miRNA). One strand of the duplex is loaded into RISC as a mature 
miRNA. The other strand, termed the star strand, is typically degraded. An asterisk (star) is 
appended to the miRNA name to designate this star strand, e.g. miR-145*. However, for 
some miRNAs both strands may be loaded into RISC at similar frequencies. In this case, the 
strand from the 5′ end of the stem-loop is termed “5p” and the 3′ strand the “3p”. In fact, 
while RISC loading may strongly favor incorporation of one strand, recent next generation 
sequencing (NGS) efforts have demonstrated a small fraction of star strand loaded for 
essentially all miRNA families[51]. Further complicating the nomenclature, some miRNAs 
show different strand usage depending on cell type or biological state[52]. For these reasons, 
5p/3p naming schemes are being increasingly used rather than the arbitrary mature/star 
nomenclature.
The specific nucleotide locations of Drosha and Dicer cleavage are usually narrowly 
defined, leading to mature miRNAs with clearly defined terminal ends. Some miRNAs, 
however, have heterogenous cleavage sites, leading to multiple “isomiRs” of the mature 
miRNA[53, 54]. This heterogeneity could lead to differential target repression and distinct 
biological activities. IsomiR preference can vary by cell type and isomiR switching has been 
detected in disease[52, 55, 56]. The molecular mechanism for isomiR switching is unclear.
2.3. RISC loading and target repression
The ultimate fate of the miRNA is to be incorporated into RISC (or miRISC). The exact 
composition of this protein complex is not clear but contains the essential protein 
Argonaute, of which four family members have been identified in humans (Ago1-4)[57, 58]. 
After Dicer cleavage, the miRNA duplex is loaded into RISC and the star strand is removed 
by one of several possible mechanisms. If the miRNA duplex has complementarity in the 
central region, the star strand can be cut by Ago2 and further degraded by the nuclease 
complex C3PO[59-62]. This is the mechanism for RISC loading for the related siRNA 
pathway. Most miRNA duplexes, however, lack central complementarity and therefore 
cannot participate in star strand cleavage. These miRNA duplexes rely on strand unwinding, 
and several helicases have been described to possess this activity[63-67].
Argonaute directly binds the mature miRNA and seeks target mRNAs that have 
complementarity to the miRNA. In particular, nucleotides 2-7 of the miRNA, termed the 
“seed” region, are important for target association[68-70]. The 3′ end of the miRNA can also 
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contribute to target recognition, and centrally matched targets have been identified[71-74]. If 
complementarity exists in the central region of the miRNA (nucleotides 9-11) then the 
mRNA target can be cleaved via the endonuclease activity of Ago2[75, 76]. Most miRNA 
targets in humans, however, lack this central sequence match and are not directly cleaved by 
Ago2. Rather, Argonaute is recruited to a complex containing GW182 (TNRC6A/B/C) 
within cytoplasmic P bodies where translational repression occurs. The CCR4-NOT 
deadenylase complex is recruited to RISC and this facilitates removal of the poly(A) tail and 
eventual degradation of the mRNA target [77-79].
2.4. Alternative pathways
While the majority of identified miRNAs are produced by the canonical pathway there are 
several examples of alternative biogenesis. The most common variation is the mirtron class 
of miRNAs[80-83]. These miRNAs, located in introns at the exon junction site, bypass the 
Drosha step. Instead, the precursor ends are formed by the splicing cleavage events. The 
resultant precursor stem loop is processed by Dicer and loaded into RISC. Dicer 
independent miRNA biogenesis has also been described[84-86]. The best studied example is 
miR-451. After transcription and Drosha cleavage the precursor directly binds Ago2, instead 
of Dicer, and Ago2 cleaves the star strand (like it would cleave a target RNA). The 
remaining loop sequence is trimmed back to yield the pre-loaded, mature miR-451. Other 
miRNAs may follow this same pathway[87]. These non-canonical pathways are of particular 
relevance when interpreting data from Dicer or Drosha/DGCR8 knockout studies.
While the aforementioned RNAs are mature miRNAs that are generated through non-
canonical routes, there are other classes of small RNAs that are not miRNAs, yet are 
produced by Drosha and/or Dicer activity and bound to RISC[88]. The best characterized 
class of these RNAs is the tRNA derived small RNA fragments (tRF or tsRNAs). These 
RNAs are a similar size to miRNAs and can be moderately abundant. Some tsRNAs are 
produced by Dicer cleavage of mature tRNAs and are loaded into RISC[89, 90]. Another 
class is derived from outside the mature tRNA and is generated by the tRNA splicing 
reaction[89, 90]. Examples of these RNAs are able to repress gene expression similar to 
conventional miRNAs, and have been shown to have essential cellular functions[90].
Further complicating the model, several studies have suggested that miRNAs can function 
independent of the RISC complex. A quantitative analysis of the total miRNA population in 
a cell, compared to the RISC protein copy number, suggested that a large fraction of 
miRNAs are not associated with RISC[91]. The functional roles of these RISC-free miRNAs 
are not known. However, one miRNA, miR-328, has been reported to be in a complex with 
the RNA binding protein hnRNP E2[92]. This miRNA functionally blocks association of the 
RNP with its target mRNA C/EBPα, enhancing translation of the C/EBP protein. It should 
be noted that these non-canonical pathways appear to be rare events. For example, miR-328 
predominantly functions as a canonical miRNA within the RISC complex, directing 
translational repression of target mRNAs[93-97].
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3. miRNA target identification
Defining target sets for miRNAs is important for several reasons. For biologists, defining the 
target set of a miRNA is key to understanding its biological role. For scientists developing 
miRNA therapeutics, validated targets provide the best biomarker(s) for determination of the 
efficacy of a miRNA mimic or inhibitor. The identification of miRNA targets has followed 
three general approaches: bioinformatic target prediction, biochemical isolation of miRNA/
mRNA complexes, and transcriptomic/proteomic analysis. The three approaches will be 
briefly summarized.
3.1. Bioinformatic target prediction
Since miRNAs base pair with target mRNAs using standard Watson-Crick rules, this fact 
should make bioinformatic target identification straightforward. Unfortunately, the most 
important determinant of target binding is the seed sequence of the miRNA which is only 6 
nucleotides in length. This will lead to a great number of candidate targets, many of which 
are false negatives. Therefore, all bioinformatic target prediction algorithms use additional 
factors to improve accuracy[98]. Since the best characterized targets are in mRNA 3′ 
untranslated regions, many algorithms limit target sites to this region. Other factors are 
employed, including sequence conservation, target site accessibility, flanking sequence 
determinants, and compensatory pairing outside the seed region. Current approaches have 
also used machine learning algorithms that incorporate validated targets in the learning 
sets[98]. A number of algorithms have been developed, with TargetScan, miRanda, and 
PicTar perhaps the most popular[69, 99-101]. In general, bioinformatic approaches are a 
good starting point for miRNA analysis and many research labs make use of them[102, 
103].
3.2. Biochemical target identification
Several related approaches have used physical association of miRNA/RISC complexes with 
target mRNAs to isolate and identify targets. These are based on immunoprecipitation of 
RISC using anti-Argonaute antibodies, with or without prior RNA crosslinking, and 
definition of bound target RNAs by microarray or NGS profiling[104-107]. Crosslinking 
before cell lysis is generally preferred since artifactual RNA associations have been 
observed during cell lysis[108]. An alternative approach is isolation of specific biotinylated 
miRNAs followed by target identification[109, 110]. This has the advantage of capturing 
targets of a single known miRNA, but requires ectopic introduction of the biotinylated 
miRNA. While these physical approaches have been successfully used to define binding 
partners of miRNA complexes, not all bound mRNA targets may be biologically repressed 
targets. Studies have reported that some target sites, often in coding sequences of mRNAs, 
are bound to Argonaute but are not repressed targets[104]. Like all approaches, validation of 
individual targets is essential.
3.3. Omics -based strategies for target identification
The third general approach to target identification is a proteomic or transcriptomic analysis 
of cells/tissues in the presence and absence of a miRNA. Quantitative proteomic analysis 
directly measures the effect of a miRNA on protein production, and is possibly more 
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reflective of the true target set, but is also technically challenging. Since most miRNA 
targets have reduced mRNA steady state levels, the simpler transcriptome analysis can be 
performed[111]. This can be done by microarray profiling and several analysis tools are 
available[112-115]. An example of this approach is the identification of targets of the 
neutrophil-specific miRNA miR-223[116]. Neutrophils were isolated from wild type and 
miR-223 knockout mice. Microarray and quantitative mass spectrometry were performed, 
and differences in mRNA and protein content was used to define targets of miR-223. It 
should be noted that the candidate target sets will also contain downstream secondary 
targets, requiring validation of individual targets.
4. Regulation of the miRNA pathway
Early work in the field focused on transcriptional regulation of miRNA host genes[25, 26, 
117, 118]. For example, the cardiac-specific miRNA families miR-1 and miR-133 are 
transcriptionally regulated by well established cardiomyocyte transcription factor networks 
via SRF, MEF2, and MyoD[119-123]. Accordingly, enhancer elements for these factors 
have been identified in upstream regions of the miR-1/133 host genes. Similarly, miRNAs 
that are located in introns of protein coding genes are often regulated by the same 
transcription factor networks that control the protein coding mRNA. In general, approaches 
that have been used for mRNA promoter analysis will work similarly for miRNA promoters.
In addition to transcriptional regulation, miRNA production is often controlled during post-
transcriptional biogenesis steps[34]. A well studied example of this is the regulation of the 
let-7 family during differentiation of embryonic cells. In stem cells the levels of mature let-7 
are virtually undetectable. During differentiation, let-7 expression increases over a hundred 
fold, becoming one of the most abundant miRNA families in differentiated cells of a variety 
of cell types. Interestingly, transcription of the let-7 host genes does not increase 
significantly[124]. Rather, let-7 maturation is blocked in embryonic cells by the RNA 
binding protein Lin28[125-127]. This protein directly binds to the loop region of the pri-
miRNA and precursor and inhibits Drosha and Dicer cleavage, respectively[128-130]. In a 
secondary repressive mechanism, Lin28 directs the uridyl transferase enzyme Tut4 to add an 
oligouridine tail to let-7 precursors, marking them for degradation[131-134]. During cellular 
differentiation, Lin28 expression is shut down allowing maturation of abundant lt-7 pri-
miRNAs. More recently, other RNA binding proteins have been linked to the regulation of 
miRNA biogenesis, with activating and repressing roles described[135-138]. Regulated 
degradation of specific miRNAs has also been described[139].
5. Biological roles of miRNAs
The biological importance of miRNAs in mammalian development was first demonstrated 
with the generation of mouse models deficient for Dicer and DGCR8 (Drosha is involved in 
other RNA metabolic pathways while DGCR8 is specific for miRNA biogenesis, thus the 
DGCR8 knockout is more informative). Loss of either step in miRNA biogenesis results in 
embryonic lethality[140, 141]. Similarly, tissue-specific knockout of either gene leads to 
developmental defects in that tissue, underscoring the requirement for miRNA function in 
most tissue types[142]. Of course, knockout of these genes leads to loss of all miRNAs 
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(except for the rare non-canonical miRNAs, described above); therefore, it is difficult to 
assign roles for specific miRNAs in the development of those tissues. This has been 
addressed by miRNA knockout mouse models[142, 143]. In general, individual miRNAs are 
not required for specification of individual tissues. For example, mice lacking the cardiac 
specific miRNA miR-208 still develop a heart[144, 145]. Rather, miRNAs are often required 
for maintaining tissue homeostasis. In the heart example, miR-208 deficient animals have 
defects in stress response and exhibit cardiac hypertrophy. miRNAs may be necessary for 
maintaining tissue differentiation state, since many tissue-restricted miRNAs are reduced in 
diseases, including cancer (see below).
Transgenic overexpression studies are another approach for the identification of the 
biological roles of individual miRNAs. These studies have the disadvantage of 
overexpression artifacts that could lead to misinterpretation of data. However, they have 
been used to uncover biological roles that have not been detected in knockout studies due to 
miRNA family redundancy. Furthermore, miRNA expression is often altered in disease, and 
overexpression studies can mimic this pathological condition (see below). The above-
mentioned approaches, along with miRNA target network identification, have revealed roles 
for the miRNA pathway in the development and/or function of most tissues in the body. 
miRNAs have been linked to numerous aspects of neuronal function, including 
developmental remodeling, amygdala-dependent memory formation, dendritic spine 
development, and post-mitotic neuron cell survival [146-149]. miRNAs have been linked to 
the function of many hematopoietic lineages including neutrophils, lymphocytes, 
erythrocytes, megakaryocytes, an hematopoetic stem cells [17, 150-161]. These examples 
are a limited subset of the described functions of miRNAs in normal human biology.
6. Dysregulation of miRNAs in disease
Gene expression profiling studies have demonstrated alterations in miRNA expression in a 
wide range of human disease. In many cases, functional studies have linked miRNA 
dysregulation as a causal factor in disease progression. This section will summarize some of 
the disease states that have been linked to miRNA alterations.
6.1. Cancer
Alterations in miRNA expression have now been demonstrated in many cancer types. Early 
studies were performed using microarray, RT-PCR, and bead-based hybridization 
(Luminex) platforms, while more recent studies have used NGS-based profiling[117, 
162-167]. miRNAs have been identified that are elevated in cancer, for example miR-21 and 
the miR-17-92 cluster, while other miRNA families are frequently downregulated in cancer, 
including the let-7 and miR-34 families[168]. Tissue specific miRNAs are often reduced in 
cancer: for example, the liver-specific miR-122 in hepatocellular carcinoma[169, 170]. This 
supports the hypothesis that many miRNA families reinforce cellular differentiation state, 
and reductions in these miRNAs may allow pathological reduction in differentiation or cell 
state. Functional studies have supported the role of some miRNAs in promoting or 
preventing cancer development and progression. A well established example is the 
miR-17-92 cluster. This cluster of six miRNAs is elevated in many cancer types, most 
notably in several lymphomas and leukemias[171]. Many studies have demonstrated that 
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this miRNA cluster can promote cancer when ectopically expressed, often in cooperation 
with the oncogene c-Myc[172-175]. miR-34 is another notable cancer-associated miRNA 
family[176]. Comprised of three family members, these miRNAs are directly transactivated 
by p53 and function in parallel with p21 and Bcl2 family proteins to promote cell cycle 
arrest and apoptosis. Interestingly, this miRNA is at the focus of a frequent deletion in 
neuroblastoma. The functional importance of these miRNAs in cancer pathogenesis presents 
a strong case for their development as therapeutic targets[177].
Many other miRNA families are altered in cancers, and large scale profiling studies have 
uncovered signatures for cancer types and subtypes[178]. There is significant interest in 
developing miRNA signatures as clinical diagnostics.
6.2. Metabolic disease
miRNAs have been linked to several metabolic pathways, including cholesterol and fatty 
acid metabolism and transport, pancreatic islet function, and glucose metabolism[179]. 
miR-122 was introduced in an earlier section as a liver-specific miRNA, and is in fact the 
most abundantly expressed miRNA in hepatocytes. Targeted deletion of miR-122 in mouse 
models leads to reduced serum cholesterol and triglyceride levels[180, 181]. This effect was 
also observed in mouse and primate studies whereby miR-122 was inhibited by an antisense 
oligonucleotide[182, 183]. The effect on serum cholesterol is due in part to reduction in 
cholesterol biosynthetic enzyme expression in hepatocytes. miR-33 has been linked to serum 
high density lipoprotein (HDL) and triglyceride levels, though it is not clear if this is a 
hepatocyte-specific event or if expression in macrophages, among other cells, is controlling 
lipid metabolic regulatory networks[184-187]. Both of these miRNAs are being investigated 
as potential therapeutic targets.
Several miRNA families have been linked to glucose metabolism. miR-375 is highly 
expressed in pancreatic islet cells and regulates a large number of genes involved in islet cell 
proliferation and function[188, 189]. Let-7 has also been linked to glucose metabolism. 
Transgenic overexpression of let-7 in the pancreas leads to reduced glucose tolerance, while 
overexpression of the let-7 inhibitory protein Lin28 improves glucose uptake[190, 191]. The 
miR-103/107 family has also been functionally linked to glucose metabolism[192].
6.3. Viral pathogenesis
Several interesting connections have been made between miRNAs and virus biology. To 
date, 522 viral-encoded miRNAs have been discovered, most notably in the herpesvirus 
family[13]. While these miRNAs are not essential for virus replication, at least in the 
examples studied so far, there is evidence that miRNAs impact virus pathogenesis[193]. 
Functional studies have forged a link between viral miRNAs and the latent/lytic phase 
transition as well as host inflammatory response. This presents an interesting therapeutic 
option since these miRNAs are not in the human genome and interfering with their function 
should not have undesired side-effects.
Perhaps the most interesting example of a role for a miRNA in viral pathogenesis is the 
connection between miR-122 and hepatitis C virus (HCV). miR-122, highly expressed in 
hepatocytes, is required for efficient replication of the HCV virus[194]. Surprisingly, 
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miR-122 enhances replication HCV by promoting stability of the viral genomic RNA (in 
contrast to the conventional role of miRNAs in reducing target mRNA stability). Mutation 
of either miR-122 binding site in the HCV genome results in decreased viral RNA stability 
and virus replication[195, 196]. The reason HCV evolved to use a host cell miRNA is not 
clear, but may involve host cell trophism. A miR-122 inhibitor is undergoing clinical trials 
as an HCV therapeutic[197].
7. miRNAs as diagnostic markers
The extensive alterations in miRNA expression in disease provide great potential for clinical 
diagnostics based on miRNA signatures. Furthermore, miRNAs are more stable than 
mRNAs and can be recovered from formalin fixed paraffin sections (FFPE) and other 
sources with low overall RNA quality[198-200]. Current focus is on developing miRNA 
signatures for disease diagnosis, identifying cancers of unknown primary, and predicting 
response to therapy and drug resistance[201-208]. As yet, no in vitro diagnostic (IVD) using 
miRNA signatures has received FDA approval. However, a number of companies are 
offering Laboratory Developed Tests (LDT) that use miRNA signatures for cancer 
diagnostics[209, 210].
7.1. miRNA detection methods
miRNA detection methods can be divided into two general categories[211]. Discovery 
methods are designed to profile the expression of many miRNAs at once, often with high 
throughput. These approaches are largely centered on microarray hybridization and NGS 
profiling. The latter is especially powerful since it is possible to characterize novel miRNAs, 
while most other methods are limited to detection of known miRNA sequences. There are 
several NGS platforms available but all begin with the construction of template libraries. 
RNA adapters are ligated to both ends of small RNA fractions and the targets are RT-PCR 
amplified with primers directed at the adapters. This process amplifies all RNAs in the 
desired size range. The libraries can then be sequenced on several instruments, with the 
Illumina platforms probably the most common. Alternatively, single molecule instruments 
are available that avoid the PCR amplification step altogether[212, 213]. Since current 
instruments are capable of 200 million or more reads per library run, it is possible to 
multiplex 48 libraries (or more) in a single run and still achieve adequate sequence read 
depth[211]. Sequence reads are counted and quantitative expression profiles are obtained. 
As stated above, novel miRNAs and other small RNA species can be identified. While NGS 
based profiling has clear advantages and is becoming the default technology, nucleotide 
biases incurred during ligation steps has been observed[214, 215]. As with any profiling 
method a validation step is essential.
While NGS platforms are capable of high throughput profiling of the entire miRNA 
population, most clinical diagnostic approaches are based on rapid analysis of a small gene 
signature set. Therefore, RT-PCR and Nanostring are the focus of current diagnostic 
platforms[216]. Nanostring is a single molecule hybridization method that allows 
quantitation of ~500 targets, either mRNA or miRNA, in a rapid experimental run[217]. An 
example of an LDT miRNA diagnostic is the pancreatic cancer test from Asuragen[218]. 
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This RT-PCR based test uses a 7 miRNA signature to differentiate between pancreatic 
ductal adenocarcinoma and benign tissue.
7.2. miRNAs in extracellular fluids
Several years ago the startling discovery was made that miRNAs are present in human 
plasma[219, 220]. Due to the presence of RNase enzymes in plasma it was not expected that 
miRNAs would survive in this environment. It is now known that miRNAs are bound to 
protein, HDL, and/or encapsulated in lipid exosomes protecting them from 
degradation[221-227]. Originally thought to be cellular “debris” in plasma, possibly released 
from apoptotic cells, several studies have indicated that these extracellular miRNAs can be 
taken up by target cells and mediate target gene repression[228-230]. miRNA content in 
exosomes has distinct profiles from the parent cell, raising the possibility that miRNAs are 
sorted to exosomes in a controlled manner[231]. Thus, exosomes may function as 
extracellular messengers and may promote disease progression.
miRNAs have also been isolated from other extracellular fluids including saliva, urine, and 
stool[232]. Major efforts are underway to profile the miRNAs in these and other fluids, in 
normal subjects and in patients with disease[233]. Since many of these fluids can be easily 
obtained without invasive procedures they offer tremendous potential as a source material 
for clinical diagnostics. While numerous studies have reported extracellular miRNA 
signatures for diseases it remains to be determined whether these signatures have acceptable 
accuracy and sensitivity for the clinic.
8. miRNAs as therapeutic targets
As miRNAs become causally linked to increasing numbers of human diseases there are 
expanding efforts to develop therapeutics that directly target the miRNA[234-236]. These 
candidates are either miRNA mimics or antisense inhibitors, depending on the miRNA and 
underlying therapeutic goal. These drug candidates are based on modified nucleic acids and 
therefore present delivery challenges. The most promising candidate to date is the Regulus 
drug RG-101, currently in Phase II trials[197]. This drug is an antisense inhibitor of 
miR-122 that is being developed as a HCV therapeutic. A number of other miRNA 
therapeutic targets are being pursued by academia and industry, including targets for 
cardiovascular disease and cancer.
8.1. miRNA mimics and inhibitors
miRNA therapeutics fall under two general categories[234]. For miRNAs that are reduced in 
disease the therapeutic goal is to replace the miRNA. To achieve this a miRNA mimic is 
developed. These are typically dsRNA duplexes that directly load into RISC, though a stem-
loop precursor can also be employed. In this case, the precursor is cleaved by Dicer and 
loaded into RISC. Since miRNA mimics are similar to siRNAs, the design strategies that 
have been developed for siRNA therapeutics have been adapted to miRNAs. Details of these 
designs are discussed in other sections of this special issue. Briefly, the duplex RNA 
requires backbone and ribose modifications to promote stability in vivo and improve 
pharmacodynamics. Some strategy to promote cellular uptake must be included. This may 
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involve conjugation to sugar ligands or encapsulation in liposomes. Some therapeutic 
mimics that are under development are miR-34 for cancer (Phase I) and pre-clinical 
therapeutics including let-7 for cancer and miR-29 for fibrosis[237, 238].
miRNAs that are elevated in disease can be targeted by antisense oligonucleotide 
inhibitors[234]. These inhibitors bind to the miRNA, most likely in the RISC complex, and 
prevent miRNA binding to target mRNAs. As with mimics, miRNA inhibitors require 
modifications for stability, and in some cases conjugation to ligands or encapsulation. The 
best example of a miRNA inhibitor is the RG101 anti-miR-122 in Phase II trials for HCV 
infection[197].
8.2. Small molecule inhibitors of the miRNA pathway
An interesting alternative to inhibiting the disease-associated miRNA directly is to develop 
small molecule compounds that modulate production or function of the miRNA[239]. This 
would avoid the problems associated with oligonucleotide delivery in vivo. Several research 
groups have performed high throughput screens for compounds that inhibit the function of 
specific miRNAs[240-245]. The readout for these screens is often a cell-based reporter that 
is normally silenced by the miRNA. If a compound interferes with production or activity of 
the miRNA, the reporter will be desilenced and the compound scored a hit. As an example, 
compounds that inhibit the activity of the oncogenic miR-21 have been identified using this 
approach[241, 242, 244]. The disadvantage of these small molecule drugs is that, by 
definition, the mechanism of action is unknown. There is much more downstream work 
required to define the specificity and direct mode of action.
9. Genome editing approaches
The miRNA pathway is a subset of post-transcriptional gene silencing (PTGS) pathways. In 
these related biological pathways the mRNA is the target of the silencing machinery, hence 
“post-transcriptional” silencing. A complementary approach to silence gene expression is to 
target the genome itself. Several approaches have been developed to redirect an 
endonuclease to a desired target site in genomic DNA[246]. The resultant double strand 
break is repaired, usually by non-homologous end joining, generating a short deletion at the 
repair site. This “editing” event is permanent and often leads to loss of expression of the 
targeted gene.
Early strategies for genome editing were based on the FokI nuclease domain fused to DNA 
binding protein modules[246]. Zinc finger nuclease (ZFN) and transcription activator like 
effector (TALE) domains are protein domains that bind to nucleic acids with predictable 
specificity. By constructing tandem arrangements of these domain variants it is possible to 
generate a DNA targeting protein with the desired sequence specificity. This targeting 
protein, fused to FokI, can direct permanent genome editing. The major factor that limited 
the widespread use of ZFNs and TALENs is the technical difficulty in construction of the 
targeting module. Multiple cloning steps are required, and since genome editing success is 
not guaranteed, many laboratories were dissuaded from the approach. This changed with the 
discovery of the CRISPR/Cas system.
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The CRISPR/Cas pathway originates in bacterial where it functions as a primitive immune 
system[247]. Clustered regularly interspaced short palindromic repeats (CRISPR) are repeat 
sequences in bacterial genomes that are derived from pathogenic viruses. Bacteria use guide 
RNAs derived from these sequences to direct the Cas9 endonuclease to invading viruses, 
cutting the viral genome and preventing viral attack. By modifying the sequence of this 
guide RNA, it is possible to target any desired DNA sequence (see Figure 3)[248-251]. The 
resultant DNA break is repaired by NHEJ, leading to a short deletion. If a homologous DNA 
template is supplied, the break is repaired by homologous recombination, allowing precise 
control of the editing event. This approach has received rapid acceptance in molecular 
biological studies and has been used for disease modeling in cultured cells and in the 
mouse[252]. The major limitation for the use of CRISPR/Cas system as a therapeutic is that 
the Cas9 nuclease protein is bacterial in origin and must be ectopically expressed in the 
target cell. This requires the use of viral gene therapy vectors and the associated delivery 
and safety challenges that have limited clinical progress in that field. There is much 
excitement in the field, however, that CRISPR/Cas is a potential therapeutic approach, and 
studies in the mouse have demonstrated incredible potential[253].
10. Conclusion
We are entering an exciting time in the field of miRNA research. A decade of strong basic 
science research has forged links between specific miRNA alterations and many human 
diseases. We are now entering a phase where miRNA diagnostics and therapeutics can be 
developed with confidence, and several commercial efforts are underway to bring these 
developments to the clinic.
Acknowledgments
Work performed in the author's lab was supported by funding from the NIH (R01GM070674, RC1HL100108) and 
the Department of Cell Biology and Physiology.
List of abbreviations
RISC RNA induced silencing complex
MCM7 Minichromosome maintenance protein 7
DGCR8 DiGeorge Syndrome critical region 8
TRBP TAR RNA binding protein
NGS Next generation sequencing
C3PO Component 3 promoter of RISC
TNRC6 Trinucleotide repeat containing 6
CCR4-NOT carbon catabolite repression 4 negative on TATA-less complex
tRF tRNA derived fragment
tsRNA tRNA derived small RNA
Hammond Page 12













hnRNP Heterogenous nuclear ribonuclear protein
C/EBP CCAAT/enhancer binding protein
SRF Serum response factor
MEF2 Myocyte enhancer factor 2
HCV Hepatitis C virus
FDA Food and Drug Administration
LDT Laboratory developed test
FFPE Formalin fixed paraffin embedded
IVD In vitro diagnostic
siRNA small interfering RNA
PTGS Post-transcriptional gene silencing
ZFN Zinc finger nuclease
TALEN Transcription activator like effector nuclease
CRISPR Clustered regularly interspaced short palindromic repeats
NHEJ Non-homologous end joining
PAM Protospacer adjacent motif
References
1. Horvitz HR, Sulston JE. Isolation and genetic characterization of cell-lineage mutants of the 
nematode Caenorhabditis elegans. Genetics. 1980; 96:435–454. [PubMed: 7262539] 
2. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs 
with antisense complementarity to lin-14. Cell. 1993; 75:843–854. [PubMed: 8252621] 
3. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by 
lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993; 75:855–862. [PubMed: 
8252622] 
4. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun 
G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 
2000; 403:901–906. [PubMed: 10706289] 
5. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, 
Degnan B, Muller P, Spring J, Srinivasan A, Fishman M, Finnerty J, Corbo J, Levine M, Leahy P, 
Davidson E, Ruvkun G. Conservation of the sequence and temporal expression of let-7 
heterochronic regulatory RNA. Nature. 2000; 408:86–89. [PubMed: 11081512] 
6. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic 
interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391:806–811. 
[PubMed: 9486653] 
7. Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttranscriptional gene 
silencing in plants. Science. 1999; 286:950–952. [PubMed: 10542148] 
8. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP- 
dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell. 2000; 101:25–33. [PubMed: 
10778853] 
9. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post- 
transcriptional gene silencing in Drosophila cells. Nature. 2000; 404:293–296. [PubMed: 10749213] 
Hammond Page 13













10. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A cellular function 
for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. 
Science. 2001; 293:834–838. [PubMed: 11452083] 
11. Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha I, Baillie DL, Fire A, Ruvkun G, Mello 
CC. Genes and mechanisms related to RNA interference regulate expression of the small temporal 
RNAs that control C. elegans developmental timing. Cell. 2001; 106:23–34. [PubMed: 11461699] 
12. Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH. Dicer functions in RNA 
interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes 
Dev. 2001; 15:2654–2659. [PubMed: 11641272] 
13. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA 
sequences, targets and gene nomenclature. Nucleic Acids Res. 2006; 34:D140–144. [PubMed: 
16381832] 
14. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281–297. 
[PubMed: 14744438] 
15. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA 
host genes and transcription units. Genome Res. 2004; 14:1902–1910. [PubMed: 15364901] 
16. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia 
A, Fedele G, Rameh L, Loda M, Pandolfi PP. Identification of the miR-106b~25 microRNA 
cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in 
transformation. Sci Signal. 2010; 3:ra29. [PubMed: 20388916] 
17. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson 
RT, Crowley D, Stone JR, Jaenisch R, Sharp PA, Jacks T. Targeted deletion reveals essential and 
overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell. 2008; 132:875–
886. [PubMed: 18329372] 
18. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for 
small expressed RNAs. Science. 2001; 294:853–858. [PubMed: 11679670] 
19. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable 
regulatory roles in Caenorhabditis elegans. Science. 2001; 294:858–862. [PubMed: 11679671] 
20. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001; 
294:862–864. [PubMed: 11679672] 
21. Papadopoulos GL, Reczko M, Simossis VA, Sethupathy P, Hatzigeorgiou AG. The database of 
experimentally supported targets: a functional update of TarBase. Nucleic Acids Res. 2009; 
37:D155–158. [PubMed: 18957447] 
22. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. MicroRNA genes are transcribed by 
RNA polymerase II. EMBO J. 2004; 23:4051–4060. [PubMed: 15372072] 
23. Bortolin-Cavaille ML, Dance M, Weber M, Cavaille J. C19MC microRNAs are processed from 
introns of large Pol-II, non-protein-coding transcripts. Nucleic Acids Res. 2009; 37:3464–3473. 
[PubMed: 19339516] 
24. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated 
transcripts that can also function as mRNAs. RNA. 2004; 10:1957–1966. [PubMed: 15525708] 
25. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs 
modulate E2F1 expression. Nature. 2005; 435:839–843. [PubMed: 15944709] 
26. Woods K, Thomson JM, Hammond SM. Direct regulation of an oncogenic micro-RNA cluster by 
E2F transcription factors. J Biol Chem. 2007; 282:2130–2134. [PubMed: 17135268] 
27. Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S, Guenther MG, 
Johnston WK, Wernig M, Newman J, Calabrese JM, Dennis LM, Volkert TL, Gupta S, Love J, 
Hannett N, Sharp PA, Bartel DP, Jaenisch R, Young RA. Connecting microRNA genes to the core 
transcriptional regulatory circuitry of embryonic stem cells. Cell. 2008; 134:521–533. [PubMed: 
18692474] 
28. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, 
Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT. 
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. 
Mol Cell. 2007; 26:745–752. [PubMed: 17540599] 
Hammond Page 14













29. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren 
M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007; 
26:731–743. [PubMed: 17540598] 
30. He L, He X, Lim LP, de Stanchina E, Xuan Z, Yamakuchi, Liang W, Xue L, Zender J, Magnus D, 
Ridzon AL, Jackson PS, Linsley C, Chen SW, Lowe MA, Cleary GJ, Hannon. A microRNA 
component of the p53 tumour suppressor network. Nature. 2007; 447:1130–1134. [PubMed: 
17554337] 
31. Georgakilas G, Vlachos IS, Paraskevopoulou MD, Yang P, Zhang Y, Economides AN, 
Hatzigeorgiou AG. microTSS: accurate microRNA transcription start site identification reveals a 
significant number of divergent pri-miRNAs. Nat Commun. 2014; 5:5700. [PubMed: 25492647] 
32. Bhattacharyya M, Feuerbach L, Bhadra T, Lengauer T, Bandyopadhyay S. MicroRNA 
transcription start site prediction with multi-objective feature selection. Stat Appl Genet Mol Biol. 
2012; 11 Article 6. 
33. Ozsolak F, Poling LL, Wang Z, Liu H, Liu XS, Roeder RG, Zhang X, Song JS, Fisher DE. 
Chromatin structure analyses identify miRNA promoters. Genes Dev. 2008; 22:3172–3183. 
[PubMed: 19056895] 
34. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009; 
10:126–139. [PubMed: 19165215] 
35. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN. The 
nuclear RNase III Drosha initiates microRNA processing. Nature. 2003; 425:415–419. [PubMed: 
14508493] 
36. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and 
subcellular localization. EMBO J. 2002; 21:4663–4670. [PubMed: 12198168] 
37. Ballarino M, Pagano F, Girardi E, Morlando M, Cacchiarelli D, Marchioni M, Proudfoot NJ, 
Bozzoni I. Coupled RNA processing and transcription of intergenic primary microRNAs. Mol Cell 
Biol. 2009; 29:5632–5638. [PubMed: 19667074] 
38. Morlando M, Ballarino M, Gromak N, Pagano F, Bozzoni I, Proudfoot NJ. Primary microRNA 
transcripts are processed co-transcriptionally. Nat Struct Mol Biol. 2008; 15:902–909. [PubMed: 
19172742] 
39. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex in primary 
microRNA processing. Genes Dev. 2004; 18:3016–3027. [PubMed: 15574589] 
40. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, Shiekhattar R. The 
Microprocessor complex mediates the genesis of microRNAs. Nature. 2004; 432:235–240. 
[PubMed: 15531877] 
41. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by 
the Microprocessor complex. Nature. 2004; 432:231–235. [PubMed: 15531879] 
42. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs 
and short hairpin RNAs. Genes Dev. 2003; 17:3011–3016. [PubMed: 14681208] 
43. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. 
Science. 2004; 303:95–98. [PubMed: 14631048] 
44. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding 
protein that mediates nuclear export of pre-miRNAs. RNA. 2004; 10:185–191. [PubMed: 
14730017] 
45. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the 
initiation step of RNA interference. Nature. 2001; 409:363–366. [PubMed: 11201747] 
46. Maniataki E, Mourelatos Z. A human, ATP-independent, RISC assembly machine fueled by pre 
miRNA. Genes Dev. 2005; 19:2979–2990. [PubMed: 16357216] 
47. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA 
biogenesis and posttranscriptional gene silencing. Cell. 2005; 123:631–640. [PubMed: 16271387] 
48. Gatignol A, Laine S, Clerzius G. Dual role of TRBP in HIV replication and RNA interference: 
viral diversion of a cellular pathway or evasion from antiviral immunity? Retrovirology. 2005; 
2:65. [PubMed: 16253139] 
Hammond Page 15













49. Haase AD, Jaskiewicz L, Zhang H, Laine S, Sack R, Gatignol A, Filipowicz W. TRBP, a regulator 
of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing. 
EMBO Rep. 2005; 6:961–967. [PubMed: 16142218] 
50. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K, Shiekhattar R. 
TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature. 
2005; 436:740–744. [PubMed: 15973356] 
51. Yang JS, Phillips MD, Betel D, Mu P, Ventura A, Siepel AC, Chen KC, Lai EC. Widespread 
regulatory activity of vertebrate microRNA* species. RNA. 2011; 17:312–326. [PubMed: 
21177881] 
52. Ohanian M, Humphreys DT, Anderson E, Preiss T, Fatkin D. A heterozygous variant in the human 
cardiac miR-133 gene, MIR133A2, alters miRNA duplex processing and strand abundance. BMC 
Genet. 2013; 14:18. [PubMed: 23497314] 
53. Lee LW, Zhang S, Etheridge A, Ma L, Martin D, Galas D, Wang K. Complexity of the microRNA 
repertoire revealed by next-generation sequencing. RNA. 2010; 16:2170–2180. [PubMed: 
20876832] 
54. Marti E, Pantano L, Banez-Coronel M, Llorens F, Minones-Moyano E, Porta S, Sumoy L, Ferrer I, 
Estivill X. A myriad of miRNA variants in control and Huntington's disease brain regions detected 
by massively parallel sequencing. Nucleic Acids Res. 2010; 38:7219–7235. [PubMed: 20591823] 
55. Baran-Gale J, Fannin EE, Kurtz CL, Sethupathy P. Beta Cell 5'-Shifted isomiRs Are Candidate 
Regulatory Hubs in Type 2 Diabetes. PLoS One. 2013; 8:e73240. [PubMed: 24039891] 
56. Vickers KC, Sethupathy P, Baran-Gale J, Remaley AT. Complexity of microRNA function and the 
role of isomiRs in lipid homeostasis. J Lipid Res. 2013; 54:1182–1191. [PubMed: 23505317] 
57. Hammond SM, Boettcher S, Caudy AA, Kobayashi R, Hannon GJ. Argonaute2, a link between 
genetic and biochemical analyses of RNAi. Science. 2001; 293:1146–1150. [PubMed: 11498593] 
58. Tabara H, Sarkissian M, Kelly WG, Fleenor J, Grishok A, Timmons L, Fire A, Mello CC. The 
rde-1 gene, RNA interference, and transposon silencing in C. elegans. Cell. 1999; 99:123–132. 
[PubMed: 10535731] 
59. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates 
assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell. 2005; 123:607–620. 
[PubMed: 16271386] 
60. Shin C. Cleavage of the star strand facilitates assembly of some microRNAs into Ago2-containing 
silencing complexes in mammals. Mol Cells. 2008; 26:308–313. [PubMed: 18728384] 
61. Liu Y, Ye X, Jiang F, Liang C, Chen D, Peng J, Kinch LN, Grishin NV, Liu Q. C3PO, an 
endoribonuclease that promotes RNAi by facilitating RISC activation. Science. 2009; 325:750–
753. [PubMed: 19661431] 
62. Ye X, Huang N, Liu Y, Paroo Z, Huerta C, Li P, Chen S, Liu Q, Zhang H. Structure of C3PO and 
mechanism of human RISC activation. Nat Struct Mol Biol. 2011; 18:650–657. [PubMed: 
21552258] 
63. Tomari Y, Du T, Haley B, Schwarz DS, Bennett R, Cook HA, Koppetsch BS, Theurkauf WE, 
Zamore PD. RISC assembly defects in the Drosophila RNAi mutant armitage. Cell. 2004; 
116:831–841. [PubMed: 15035985] 
64. Meister G, Landthaler M, Peters L, Chen PY, Urlaub H, Luhrmann R, Tuschl T. Identification of 
novel argonaute-associated proteins. Curr Biol. 2005; 15:2149–2155. [PubMed: 16289642] 
65. Nykanen A, Haley B, Zamore PD. ATP requirements and small interfering RNA structure in the 
RNA interference pathway. Cell. 2001; 107:309–321. [PubMed: 11701122] 
66. Robb GB, Rana TM. RNA helicase A interacts with RISC in human cells and functions in RISC 
loading. Mol Cell. 2007; 26:523–537. [PubMed: 17531811] 
67. Liu X, Jin DY, McManus MT, Mourelatos Z. Precursor microRNA-programmed silencing 
complex assembly pathways in mammals. Mol Cell. 2012; 46:507–517. [PubMed: 22503104] 
68. Lai EC, Tam B, Rubin GM. Pervasive regulation of Drosophila Notch target genes by GY-box-, 
Brd-box-, and K-box-class microRNAs. Genes Dev. 2005; 19:1067–1080. [PubMed: 15833912] 
69. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian 
microRNA targets. Cell. 2003; 115:787–798. [PubMed: 14697198] 
Hammond Page 16













70. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS. 
Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. 2003; 21:635–
637. [PubMed: 12754523] 
71. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting 
specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007; 27:91–105. [PubMed: 
17612493] 
72. Shin C, Nam JW, Farh KK, Chiang HR, Shkumatava A, Bartel DP. Expanding the microRNA 
targeting code: functional sites with centered pairing. Mol Cell. 2010; 38:789–802. [PubMed: 
20620952] 
73. Helwak A, Kudla G, Dudnakova T, Tollervey D. Mapping the human miRNA interactome by 
CLASH reveals frequent noncanonical binding. Cell. 2013; 153:654–665. [PubMed: 23622248] 
74. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B, Rigoutsos I. A pattern-
based method for the identification of MicroRNA binding sites and their corresponding 
heteroduplexes. Cell. 2006; 126:1203–1217. [PubMed: 16990141] 
75. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, 
Hannon GJ. Argonaute2 is the catalytic engine of mammalian RNAi. Science. 2004; 305:1437–
1441. [PubMed: 15284456] 
76. Doench JG, Petersen CP, Sharp PA. siRNAs can function as miRNAs. Genes Dev. 2003; 17:438–
442. [PubMed: 12600936] 
77. Pfaff J, Meister G. Argonaute and GW182 proteins: an effective alliance in gene silencing. 
Biochem Soc Trans. 2013; 41:855–860. [PubMed: 23863144] 
78. Braun JE, Huntzinger E, Izaurralde E. The role of GW182 proteins in miRNA-mediated gene 
silencing. Adv Exp Med Biol. 2013; 768:147–163. [PubMed: 23224969] 
79. Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the 
hood of miRISC. Nat Struct Mol Biol. 2012; 19:586–593. [PubMed: 22664986] 
80. Ruby JG, Jan CH, Bartel DP. Intronic microRNA precursors that bypass Drosha processing. 
Nature. 2007; 448:83–86. [PubMed: 17589500] 
81. Berezikov E, Chung WJ, Willis J, Cuppen E, Lai EC. Mammalian mirtron genes. Mol Cell. 2007; 
28:328–336. [PubMed: 17964270] 
82. Okamura K, Hagen JW, Duan H, Tyler DM, Lai EC. The mirtron pathway generates microRNA-
class regulatory RNAs in Drosophila. Cell. 2007; 130:89–100. [PubMed: 17599402] 
83. Babiarz JE, Ruby JG, Wang Y, Bartel DP, Blelloch R. Mouse ES cells express endogenous 
shRNAs, siRNAs, and other Microprocessor-independent, Dicer-dependent small RNAs. Genes 
Dev. 2008; 22:2773–2785. [PubMed: 18923076] 
84. Cheloufi S, Dos Santos CO, Chong MM, Hannon GJ. A dicer-independent miRNA biogenesis 
pathway that requires Ago catalysis. Nature. 2010; 465:584–589. [PubMed: 20424607] 
85. Cifuentes D, Xue H, Taylor DW, Patnode H, Mishima Y, Cheloufi S, Ma E, Mane S, Hannon GJ, 
Lawson ND, Wolfe SA, Giraldez AJ. A novel miRNA processing pathway independent of Dicer 
requires Argonaute2 catalytic activity. Science. 2010; 328:1694–1698. [PubMed: 20448148] 
86. Yang JS, Lai EC. Dicer-independent, Ago2-mediated microRNA biogenesis in vertebrates. Cell 
Cycle. 2010; 9:4455–4460. [PubMed: 21088485] 
87. Diederichs S, Haber DA. Dual role for argonautes in microRNA processing and posttranscriptional 
regulation of microRNA expression. Cell. 2007; 131:1097–1108. [PubMed: 18083100] 
88. Garcia-Silva MR, Cabrera-Cabrera F, Guida MC, Cayota A. Hints of tRNA-Derived Small RNAs 
Role in RNA Silencing Mechanisms. Genes (Basel). 2012; 3:603–614. [PubMed: 24705078] 
89. Haussecker D, Huang Y, Lau A, Parameswaran P, Fire AZ, Kay MA. Human tRNA-derived small 
RNAs in the global regulation of RNA silencing. RNA. 2010; 16:673–695. [PubMed: 20181738] 
90. Lee YS, Shibata Y, Malhotra A, Dutta A. A novel class of small RNAs: tRNA-derived RNA 
fragments (tRFs). Genes Dev. 2009; 23:2639–2649. [PubMed: 19933153] 
91. Janas MM, Wang B, Harris AS, Aguiar M, Shaffer JM, Subrahmanyam YV, Behlke MA, 
Wucherpfennig KW, Gygi SP, Gagnon E, Novina CD. Alternative RISC assembly: binding and 
repression of microRNA-mRNA duplexes by human Ago proteins. RNA. 2012; 18:2041–2055. 
[PubMed: 23019594] 
Hammond Page 17













92. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, 
Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy 
DC, Liebhaber SA, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D. 
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in 
leukemic blasts. Cell. 2010; 140:652–665. [PubMed: 20211135] 
93. Paduano F, Dattilo V, Narciso D, Bilotta A, Gaudio E, Menniti M, Agosti V, Palmieri C, Perrotti 
N, Fusco A, Trapasso F, Iuliano R. Protein tyrosine phosphatase PTPRJ is negatively regulated by 
microRNA-328. FEBS J. 2013; 280:401–412. [PubMed: 22564856] 
94. Turrini E, Haenisch S, Laechelt S, Diewock T, Bruhn O, Cascorbi I. MicroRNA profiling in K-562 
cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. 
Pharmacogenet Genomics. 2012; 22:198–205. [PubMed: 22241070] 
95. Boissonneault V, Plante I, Rivest S, Provost P. MicroRNA-298 and microRNA-328 regulate 
expression of mouse beta-amyloid precursor protein-converting enzyme 1. J Biol Chem. 2009; 
284:1971–1981. [PubMed: 18986979] 
96. Wang CH, Lee DY, Deng Z, Jeyapalan Z, Lee SC, Kahai S, Lu WY, Zhang Y, Yang BB. 
MicroRNA miR-328 regulates zonation morphogenesis by targeting CD44 expression. PLoS One. 
2008; 3:e2420. [PubMed: 18560585] 
97. Chen KC, Hsi E, Hu CY, Chou WW, Liang CL, Juo SH. MicroRNA-328 may influence myopia 
development by mediating the PAX6 gene. Invest Ophthalmol Vis Sci. 2012; 53:2732–2739. 
[PubMed: 22447870] 
98. Ekimler S, Sahin K. Computational Methods for MicroRNA Target Prediction. Genes (Basel). 
2014; 5:671–683. [PubMed: 25153283] 
99. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of 
microRNAs. Genome Res. 2009; 19:92–105. [PubMed: 18955434] 
100. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS 
Biol. 2004; 2:e363. [PubMed: 15502875] 
101. Grun D, Wang YL, Langenberger D, Gunsalus KC, Rajewsky N. microRNA target predictions 
across seven Drosophila species and comparison to mammalian targets. PLoS Comput Biol. 
2005; 1:e13. [PubMed: 16103902] 
102. Thomas M, Lieberman J, Lal A. Desperately seeking microRNA targets. Nat Struct Mol Biol. 
2010; 17:1169–1174. [PubMed: 20924405] 
103. Huang Y, Zou Q, Song H, Song F, Wang L, Zhang G, Shen X. A study of miRNAs targets 
prediction and experimental validation. Protein Cell. 2010; 1:979–986. [PubMed: 21153515] 
104. Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, Rothballer A, Ascano 
M Jr. Jungkamp AC, Munschauer M, Ulrich A, Wardle GS, Dewell S, Zavolan M, Tuschl T. 
Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-
CLIP. Cell. 2010; 141:129–141. [PubMed: 20371350] 
105. Chi SW, Zang JB, Mele A, Darnell RB. Argonaute HITS-CLIP decodes microRNA-mRNA 
interaction maps. Nature. 2009; 460:479–486. [PubMed: 19536157] 
106. Karginov FV, Conaco C, Xuan Z, Schmidt BH, Parker JS, Mandel G, Hannon GJ. A biochemical 
approach to identifying microRNA targets. Proc Natl Acad Sci U S A. 2007; 104:19291–19296. 
[PubMed: 18042700] 
107. Leung AK, Young AG, Bhutkar A, Zheng GX, Bosson AD, Nielsen CB, Sharp PA. Genome-
wide identification of Ago2 binding sites from mouse embryonic stem cells with and without 
mature microRNAs. Nat Struct Mol Biol. 2011; 18:237–244. [PubMed: 21258322] 
108. Riley KJ, Yario TA, Steitz JA. Association of Argonaute proteins and microRNAs can occur after 
cell lysis. RNA. 2012; 18:1581–1585. [PubMed: 22836356] 
109. Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs 
and enhances their translation. Mol Cell. 2008; 30:460–471. [PubMed: 18498749] 
110. Lal A, Thomas MP, Altschuler G, Navarro F, O'Day E, Li XL, Concepcion C, Han YC, Thiery J, 
Rajani DK, Deutsch A, Hofmann O, Ventura A, Hide W, Lieberman J. Capture of microRNA-
bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. 
PLoS Genet. 2011; 7:e1002363. [PubMed: 22102825] 
Hammond Page 18













111. Eichhorn SW, Guo H, McGeary SE, Rodriguez-Mias RA, Shin C, Baek D, Hsu SH, Ghoshal K, 
Villen J, Bartel DP. mRNA destabilization is the dominant effect of mammalian microRNAs by 
the time substantial repression ensues. Mol Cell. 2014; 56:104–115. [PubMed: 25263593] 
112. van Dongen S, Abreu-Goodger C, Enright AJ. Detecting microRNA binding and siRNA off- 
target effects from expression data. Nat Methods. 2008; 5:1023–1025. [PubMed: 18978784] 
113. Rasmussen SH, Jacobsen A, Krogh A. cWords - systematic microRNA regulatory motif 
discovery from mRNA expression data. Silence. 2013; 4:2. [PubMed: 23688306] 
114. Diao L, Marcais A, Norton S, Chen KC. MixMir: microRNA motif discovery from gene 
expression data using mixed linear models. Nucleic Acids Res. 2014; 42:e135. [PubMed: 
25081207] 
115. Sood P, Krek A, Zavolan M, Macino G, Rajewsky N. Cell-type-specific signatures of microRNAs 
on target mRNA expression. Proc Natl Acad Sci U S A. 2006; 103:2746–2751. [PubMed: 
16477010] 
116. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on 
protein output. Nature. 2008; 455:64–71. [PubMed: 18668037] 
117. Baskerville S, Bartel DP. Microarray profiling of microRNAs reveals frequent coexpression with 
neighboring miRNAs and host genes. RNA. 2005; 11:241–247. [PubMed: 15701730] 
118. Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, Ferbeyre G, 
Chartrand P. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 2007; 282:2135–
2143. [PubMed: 17135249] 
119. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang DZ. 
The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. 
Nat Genet. 2006; 38:228–233. [PubMed: 16380711] 
120. Niu Z, Iyer D, Conway SJ, Martin JF, Ivey K, Srivastava D, Nordheim A, Schwartz RJ. Serum 
response factor orchestrates nascent sarcomerogenesis and silences the biomineralization gene 
program in the heart. Proc Natl Acad Sci U S A. 2008; 105:17824–17829. [PubMed: 19004760] 
121. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA 
that targets Hand2 during cardiogenesis. Nature. 2005; 436:214–220. [PubMed: 15951802] 
122. Liu N, Williams AH, Kim Y, McAnally J, Bezprozvannaya S, Sutherland LB, Richardson JA, 
Bassel-Duby R, Olson EN. An intragenic MEF2-dependent enhancer directs muscle-specific 
expression of microRNAs 1 and 133. Proc Natl Acad Sci U S A. 2007; 104:20844–20849. 
[PubMed: 18093911] 
123. Sweetman D, Goljanek K, Rathjen T, Oustanina S, Braun T, Dalmay T, Munsterberg A. Specific 
requirements of MRFs for the expression of muscle specific microRNAs, miR-1, miR-206 and 
miR-133. Dev Biol. 2008; 321:491–499. [PubMed: 18619954] 
124. Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, Hammond SM. Extensive 
post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev. 2006; 
20:2202–2207. [PubMed: 16882971] 
125. Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7 precursor loop 
mediates regulated microRNA processing. RNA. 2008; 14:1539–1549. [PubMed: 18566191] 
126. Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. 
Science. 2008; 320:97–100. [PubMed: 18292307] 
127. Rybak A, Fuchs H, Smirnova L, Brandt C, Pohl EE, Nitsch R, Wulczyn FG. A feedback loop 
comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. 
Nat Cell Biol. 2008; 10:987–993. [PubMed: 18604195] 
128. Nam Y, Chen C, Gregory RI, Chou JJ, Sliz P. Molecular basis for interaction of let-7 microRNAs 
with Lin28. Cell. 2011; 147:1080–1091. [PubMed: 22078496] 
129. Ali PS, Ghoshdastider U, Hoffmann J, Brutschy B, Filipek S. Recognition of the let-7g miRNA 
precursor by human Lin28B. FEBS Lett. 2012; 586:3986–3990. [PubMed: 23063642] 
130. Lightfoot HL, Bugaut A, Armisen J, Lehrbach NJ, Miska EA, Balasubramanian S. A LIN28- 
dependent structural change in pre-let-7g directly inhibits dicer processing. Biochemistry. 2011; 
50:7514–7521. [PubMed: 21815640] 
Hammond Page 19













131. Heo I, Joo C, Kim YK, Ha M, Yoon MJ, Cho J, Yeom KH, Han J, Kim VN. TUT4 in concert 
with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. Cell. 2009; 
138:696–708. [PubMed: 19703396] 
132. Hagan JP, Piskounova E, Gregory RI. Lin28 recruits the TUTase Zcchc11 to inhibit let-7 
maturation in mouse embryonic stem cells. Nat Struct Mol Biol. 2009; 16:1021–1025. [PubMed: 
19713958] 
133. Heo I, Joo C, Cho J, Ha M, Han J, Kim VN. Lin28 mediates the terminal uridylation of let-7 
precursor MicroRNA. Mol Cell. 2008; 32:276–284. [PubMed: 18951094] 
134. Lehrbach NJ, Armisen J, Lightfoot HL, Murfitt KJ, Bugaut A, Balasubramanian S, Miska EA. 
LIN-28 and the poly(U) polymerase PUP-2 regulate let-7 microRNA processing in 
Caenorhabditis elegans. Nat Struct Mol Biol. 2009; 16:1016–1020. [PubMed: 19713957] 
135. Towbin H, Wenter P, Guennewig B, Imig J, Zagalak JA, Gerber AP, Hall J. Systematic screens of 
proteins binding to synthetic microRNA precursors. Nucleic Acids Res. 2013; 41:e47. [PubMed: 
23221640] 
136. Trabucchi M, Briata P, Garcia-Mayoral M, Haase AD, Filipowicz W, Ramos A, Gherzi R, 
Rosenfeld MG. The RNA-binding protein KSRP promotes the biogenesis of a subset of 
microRNAs. Nature. 2009; 459:1010–1014. [PubMed: 19458619] 
137. Guil S, Caceres JF. The multifunctional RNA-binding protein hnRNP A1 is required for 
processing of miR-18a. Nat Struct Mol Biol. 2007; 14:591–596. [PubMed: 17558416] 
138. Newman MA, Hammond SM. Emerging paradigms of regulated microRNA processing. Genes 
Dev. 2010; 24:1086–1092. [PubMed: 20516194] 
139. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function 
and decay. Nat Rev Genet. 2010; 11:597–610. [PubMed: 20661255] 
140. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, Elledge SJ, 
Anderson KV, Hannon GJ. Dicer is essential for mouse development. Nat Genet. 2003; 35:215–
217. [PubMed: 14528307] 
141. Wang Y, Medvid R, Melton C, Jaenisch R, Blelloch R. DGCR8 is essential for microRNA 
biogenesis and silencing of embryonic stem cell self-renewal. Nat Genet. 2007; 39:380–385. 
[PubMed: 17259983] 
142. Park CY, Choi YS, McManus MT. Analysis of microRNA knockouts in mice. Hum Mol Genet. 
2010; 19:R169–175. [PubMed: 20805106] 
143. Vidigal JA, Ventura A. The biological functions of miRNAs: lessons from in vivo studies. Trends 
Cell Biol. 2014
144. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress- dependent 
cardiac growth and gene expression by a microRNA. Science. 2007; 316:575–579. [PubMed: 
17379774] 
145. van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X, Richardson JA, Kelm RJ Jr. Olson EN. 
A family of microRNAs encoded by myosin genes governs myosin expression and muscle 
performance. Dev Cell. 2009; 17:662–673. [PubMed: 19922871] 
146. Kole AJ, Swahari V, Hammond SM, Deshmukh M. miR-29b is activated during neuronal 
maturation and targets BH3-only genes to restrict apoptosis. Genes Dev. 2011; 25:125–130. 
[PubMed: 21245165] 
147. Somel M, Liu X, Tang L, Yan Z, Hu H, Guo S, Jiang X, Zhang X, Xu G, Xie G, Li N, Hu Y, 
Chen W, Paabo S, Khaitovich P. MicroRNA-driven developmental remodeling in the brain 
distinguishes humans from other primates. PLoS Biol. 2011; 9:e1001214. [PubMed: 22162950] 
148. Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M, Greenberg ME. A brain-
specific microRNA regulates dendritic spine development. Nature. 2006; 439:283–289. 
[PubMed: 16421561] 
149. Griggs EM, Young EJ, Rumbaugh G, Miller CA. MicroRNA-182 regulates amygdala- dependent 
memory formation. J Neurosci. 2013; 33:1734–1740. [PubMed: 23345246] 
150. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, Bozzoni I. A minicircuitry 
comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human 
granulopoiesis. Cell. 2005; 123:819–831. [PubMed: 16325577] 
Hammond Page 20













151. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA expressed in mature B 
and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U 
S A. 2007; 104:7080–7085. [PubMed: 17438277] 
152. Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S, Das PP, Miska EA, 
Rodriguez A, Bradley A, Smith KG, Rada C, Enright AJ, Toellner KM, Maclennan IC, Turner 
M. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. 
Immunity. 2007; 27:847–859. [PubMed: 18055230] 
153. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela 
D, Kutok JL, Schmidt-Supprian M, Rajewsky N, Yancopoulos G, Rao A, Rajewsky K. 
Regulation of the germinal center response by microRNA-155. Science. 2007; 316:604–608. 
[PubMed: 17463289] 
154. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, Rajewsky N, Bender TP, 
Rajewsky K. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. 
Cell. 2007; 131:146–159. [PubMed: 17923094] 
155. Lu J, Guo S, Ebert BL, Zhang H, Peng X, Bosco J, Pretz J, Schlanger R, Wang JY, Mak RH, 
Dombkowski DM, Preffer FI, Scadden DT, Golub TR. MicroRNA-mediated control of cell fate 
in megakaryocyte-erythrocyte progenitors. Dev Cell. 2008; 14:843–853. [PubMed: 18539114] 
156. Ben-Ami O, Pencovich N, Lotem J, Levanon D, Groner Y. A regulatory interplay between 
miR-27a and Runx1 during megakaryopoiesis. Proc Natl Acad Sci U S A. 2009; 106:238–243. 
[PubMed: 19114653] 
157. Dore LC, Amigo JD, Dos Santos CO, Zhang Z, Gai X, Tobias JW, Yu D, Klein AM, Dorman C, 
Wu W, Hardison RC, Paw BH, Weiss MJ. A GATA-1-regulated microRNA locus essential for 
erythropoiesis. Proc Natl Acad Sci U S A. 2008; 105:3333–3338. [PubMed: 18303114] 
158. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, Liuzzi F, Lulli V, Morsilli O, 
Santoro S, Valtieri M, Calin GA, Liu CG, Sorrentino A, Croce CM, Peschle C. MicroRNAs 221 
and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-
modulation. Proc Natl Acad Sci U S A. 2005; 102:18081–18086. [PubMed: 16330772] 
159. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, Brummelkamp TR, 
Fleming MD, Camargo FD. Regulation of progenitor cell proliferation and granulocyte function 
by microRNA-223. Nature. 2008; 451:1125–1129. [PubMed: 18278031] 
160. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of 
microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc 
Natl Acad Sci U S A. 2006; 103:12481–12486. [PubMed: 16885212] 
161. Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S, Bhatt D, Alder 
H, Marcucci G, Calin GA, Liu CG, Bloomfield CD, Andreeff M, Croce CM. MicroRNA 
fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A. 2006; 103:5078–
5083. [PubMed: 16549775] 
162. Thomson JM, Parker J, Perou CM, Hammond SM. A custom microarray platform for analysis of 
microRNA gene expression. Nat Methods. 2004; 1:47–53. [PubMed: 15782152] 
163. Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M, Dumitru CD, Shimizu M, 
Zupo S, Dono M, Alder H, Bullrich F, Negrini M, Croce CM. An oligonucleotide microchip for 
genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S A. 2004; 
101:9740–9744. [PubMed: 15210942] 
164. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak 
RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles 
classify human cancers. Nature. 2005; 435:834–838. [PubMed: 15944708] 
165. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar 
VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ. Real-time quantification of microRNAs by 
stem-loop RT-PCR. Nucleic Acids Res. 2005; 33:e179. [PubMed: 16314309] 
166. The Cancer Genome Atlas. http://cancergenome.nih.gov/
167. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, 
Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. Frequent deletions and down-
regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. 
Proc Natl Acad Sci U S A. 2002; 99:15524–15529. [PubMed: 12434020] 
Hammond Page 21













168. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 
2006; 6:259–269. [PubMed: 16557279] 
169. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, Jacob ST, Ghoshal K. 
Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem. 
2006; 99:671–678. [PubMed: 16924677] 
170. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. miR-122, a paradigm for the 
role of microRNAs in the liver. J Hepatol. 2008; 48:648–656. [PubMed: 18291553] 
171. Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, Yoshida Y, Seto M. Identification and 
characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant 
lymphoma. Cancer Res. 2004; 64:3087–3095. [PubMed: 15126345] 
172. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-
Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as a potential human 
oncogene. Nature. 2005; 435:828–833. [PubMed: 15944707] 
173. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders 
GH, Mendell JT, Thomas-Tikhonenko A. Augmentation of tumor angiogenesis by a Myc- 
activated microRNA cluster. Nat Genet. 2006; 38:1060–1065. [PubMed: 16878133] 
174. Lu Y, Thomson JM, Wong HY, Hammond SM, Hogan BL. Transgenic over-expression of the 
microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung 
epithelial progenitor cells. Dev Biol. 2007; 310:442–453. [PubMed: 17765889] 
175. Bonauer A, Dimmeler S. The microRNA-17-92 cluster: still a miRacle? Cell Cycle. 2009; 
8:3866–3873. [PubMed: 19887902] 
176. He L, He X, Lowe SW, Hannon GJ. microRNAs join the p53 network--another piece in the 
tumour-suppression puzzle. Nat Rev Cancer. 2007; 7:819–822. [PubMed: 17914404] 
177. Berindan-Neagoe I, Monroig Pdel C, Pasculli B, Calin GA. MicroRNAome genome: a treasure 
for cancer diagnosis and therapy. CA Cancer J Clin. 2014; 64:311–336. [PubMed: 25104502] 
178. Barbarotto E, Schmittgen TD, Calin GA. MicroRNAs and cancer: profile, profile, profile. Int J 
Cancer. 2008; 122:969–977. [PubMed: 18098138] 
179. Fernandez-Hernando C, Ramirez CM, Goedeke L, Suarez Y. MicroRNAs in metabolic disease. 
Arterioscler Thromb Vasc Biol. 2013; 33:178–185. [PubMed: 23325474] 
180. Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, Yu L, Bai S, La Perle K, Chivukula RR, 
Mao H, Wei M, Clark KR, Mendell JR, Caligiuri MA, Jacob ST, Mendell JT, Ghoshal K. 
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J 
Clin Invest. 2012; 122:2871–2883. [PubMed: 22820288] 
181. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, Hsu 
MT, Wu JC, Huang HD, Shiao MS, Hsiao M, Tsou AP. MicroRNA-122 plays a critical role in 
liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012; 122:2884–2897. [PubMed: 
22820290] 
182. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, 
McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP. 
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 
2006; 3:87–98. [PubMed: 16459310] 
183. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. Silencing of 
microRNAs in vivo with 'antagomirs'. Nature. 2005; 438:685–689. [PubMed: 16258535] 
184. Marquart TJ, Allen RM, Ory DS, Baldan A. miR-33 links SREBP-2 induction to repression of 
sterol transporters. Proc Natl Acad Sci U S A. 2010; 107:12228–12232. [PubMed: 20566875] 
185. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Naar AM. 
MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 
2010; 328:1566–1569. [PubMed: 20466882] 
186. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ, 
Fernandez-Hernando C. MiR-33 contributes to the regulation of cholesterol homeostasis. 
Science. 2010; 328:1570–1573. [PubMed: 20466885] 
187. Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, Kinoshita M, Kuwabara Y, 
Marusawa H, Iwanaga Y, Hasegawa K, Yokode M, Kimura T, Kita T. MicroRNA-33 encoded by 
Hammond Page 22













an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc 
Natl Acad Sci U S A. 2010; 107:17321–17326. [PubMed: 20855588] 
188. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, Pfeffer S, Tuschl T, 
Rajewsky N, Rorsman P, Stoffel M. A pancreatic islet-specific microRNA regulates insulin 
secretion. Nature. 2004; 432:226–230. [PubMed: 15538371] 
189. Poy MN, Hausser J, Trajkovski M, Braun M, Collins S, Rorsman P, Zavolan M, Stoffel M. 
miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci U S A. 
2009; 106:5813–5818. [PubMed: 19289822] 
190. Frost RJ, Olson EN. Control of glucose homeostasis and insulin sensitivity by the Let-7 family of 
microRNAs. Proc Natl Acad Sci U S A. 2011; 108:21075–21080. [PubMed: 22160727] 
191. Zhu H, Shyh-Chang N, Segre AV, Shinoda G, Shah SP, Einhorn WS, Takeuchi A, Engreitz JM, 
Hagan JP, Kharas MG, Urbach A, Thornton JE, Triboulet R, Gregory RI, Altshuler D, Daley 
GQ. The Lin28/let-7 axis regulates glucose metabolism. Cell. 2011; 147:81–94. [PubMed: 
21962509] 
192. Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M, Heim MH, Stoffel M. 
MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011; 474:649–653. [PubMed: 
21654750] 
193. Cullen BR. Herpesvirus microRNAs: phenotypes and functions. Curr Opin Virol. 2011; 1:211–
215. [PubMed: 21927637] 
194. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA 
abundance by a liver-specific MicroRNA. Science. 2005; 309:1577–1581. [PubMed: 16141076] 
195. Jopling CL, Schutz S, Sarnow P. Position-dependent function for a tandem microRNA miR-122-
binding site located in the hepatitis C virus RNA genome. Cell Host Microbe. 2008; 4:77–85. 
[PubMed: 18621012] 
196. Shimakami T, Yamane D, Welsch C, Hensley L, Jangra RK, Lemon SM. Base pairing between 
hepatitis C virus RNA and microRNA 122 3' of its seed sequence is essential for genome 
stabilization and production of infectious virus. J Virol. 2012; 86:7372–7383. [PubMed: 
22532678] 
197. http://www.regulusrx.com/therapeutic-areas/rg-101/
198. Nelson PT, Baldwin DA, Kloosterman WP, Kauppinen S, Plasterk RH, Mourelatos Z. RAKE and 
LNA-ISH reveal microRNA expression and localization in archival human brain. RNA. 2006; 
12:187–191. [PubMed: 16373485] 
199. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, Ju J. Systematic analysis of 
microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-
embedded samples. RNA. 2007; 13:1668–1674. [PubMed: 17698639] 
200. Lehmann U. MicroRNA-profiling in formalin-fixed paraffin-embedded specimens. Methods Mol 
Biol. 2010; 667:113–125. [PubMed: 20827530] 
201. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends 
Mol Med. 2014; 20:460–469. [PubMed: 25027972] 
202. http://www.rosettagenomics.com/pros-origin
203. Li X, Lu Y, Chen Y, Lu W, Xie X. MicroRNA profile of paclitaxel-resistant serous ovarian 
carcinoma based on formalin-fixed paraffin-embedded samples. BMC Cancer. 2013; 13:216. 
[PubMed: 23627607] 
204. Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, Giglio S, Sonego M, Cirombella R, 
Onesti EC, Pellegrini P, Califano D, Pignata S, Losito S, Canzonieri V, Sorio R, Alder H, 
Wernicke D, Stoppacciaro A, Baldassarre G, Croce CM. A microRNA signature defines 
chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci U S 
A. 2013; 110:9845–9850. [PubMed: 23697367] 
205. Dai Y, Xie CH, Neis JP, Fan CY, Vural E, Spring PM. MicroRNA expression profiles of head 
and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck. 
2011; 33:786–791. [PubMed: 21560177] 
206. Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS, Anders CK, 
Mukherjee S, Dressman HK, Barry WT, Marcom KP, Olson J, Nevins JR, Potti A. An integrated 
Hammond Page 23













approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS 
One. 2008; 3:e1908. [PubMed: 18382681] 
207. Du L, Borkowski R, Zhao Z, Ma X, Yu X, Xie XJ, Pertsemlidis A. A high-throughput screen 
identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel. RNA 
Biol. 2013; 10
208. Du L, Subauste MC, DeSevo C, Zhao Z, Baker M, Borkowski R, Schageman JJ, Greer R, Yang 
CR, Suraokar M, Wistuba II, Gazdar AF, Minna JD, Pertsemlidis A. miR-337-3p and its targets 
STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One. 2012; 
7:e39167. [PubMed: 22723956] 
209. Asuragen. 
210. RosettaGenomics. 
211. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat 
Rev Genet. 2012; 13:358–369. [PubMed: 22510765] 
212. Kapranov P, Ozsolak F, Milos PM. Profiling of short RNAs using Helicos single-molecule 
sequencing. Methods Mol Biol. 2012; 822:219–232. [PubMed: 22144202] 
213. Gu LQ, Wanunu M, Wang MX, McReynolds L, Wang Y. Detection of miRNAs with a nanopore 
single-molecule counter. Expert Rev Mol Diagn. 2012; 12:573–584. [PubMed: 22845478] 
214. Hafner M, Renwick N, Brown M, Mihailovic A, Holoch D, Lin C, Pena JT, Nusbaum JD, 
Morozov P, Ludwig J, Ojo T, Luo S, Schroth G, Tuschl T. RNA-ligase-dependent biases in 
miRNA representation in deep-sequenced small RNA cDNA libraries. RNA. 2011; 17:1697–
1712. [PubMed: 21775473] 
215. Leshkowitz D, Horn-Saban S, Parmet Y, Feldmesser E. Differences in microRNA detection 
levels are technology and sequence dependent. RNA. 2013; 19:527–538. [PubMed: 23431331] 
216. Knutsen E, Fiskaa T, Ursvik A, Jorgensen TE, Perander M, Lund E, Seternes OM, Johansen SD, 
Andreassen M. Performance Comparison of Digital microRNA Profiling Technologies Applied 
on Human Breast Cancer Cell Lines. PLoS One. 2013; 8:e75813. [PubMed: 24116077] 
217. http://www.nanostring.com/products/nCounter
218. http://asuragen.com/products-and-services/clinical-lab/mirinform-pancreas/
219. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of 
mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 
2007; 9:654–659. [PubMed: 17486113] 
220. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, 
Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt 
DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as 
stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105:10513–
10518. [PubMed: 18663219] 
221. Kharaziha P, Ceder S, Li Q, Panaretakis T. Tumor cell-derived exosomes: a message in a bottle. 
Biochim Biophys Acta. 2012; 1826:103–111. [PubMed: 22503823] 
222. Hannafon BN, Ding WQ. Intercellular Communication by Exosome-Derived microRNAs in 
Cancer. Int J Mol Sci. 2013; 14:14240–14269. [PubMed: 23839094] 
223. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating 
microRNA. Nucleic Acids Res. 2011; 39:7223–7233. [PubMed: 21609964] 
224. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are 
transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 
2011; 13:423–433. [PubMed: 21423178] 
225. Turchinovich A, Burwinkel B. Distinct AGO1 and AGO2 associated miRNA profiles in human 
cells and blood plasma. RNA Biol. 2012; 9:1066–1075. [PubMed: 22858679] 
226. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in 
plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010; 
50:298–301. [PubMed: 20146939] 
227. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, 
Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M. Argonaute2 complexes carry a 
population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad 
Sci U S A. 2011; 108:5003–5008. [PubMed: 21383194] 
Hammond Page 24













228. Hergenreider E, Heydt S, Treguer K, Boettger T, Horrevoets AJ, Zeiher AM, Scheffer MP, 
Frangakis AS, Yin X, Mayr M, Braun T, Urbich C, Boon RA, Dimmeler S. Atheroprotective 
communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell 
Biol. 2012; 14:249–256. [PubMed: 22327366] 
229. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, 
Lindenberg JL, de Gruijl TD, Wurdinger T, Middeldorp JM. Functional delivery of viral 
miRNAs via exosomes. Proc Natl Acad Sci U S A. 2010; 107:6328–6333. [PubMed: 20304794] 
230. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, Gonzalez S, Sanchez-Cabo F, 
Gonzalez MA, Bernad A, Sanchez-Madrid F. Unidirectional transfer of microRNA-loaded 
exosomes from T cells to antigen-presenting cells. Nat Commun. 2011; 2:282. [PubMed: 
21505438] 
231. Koppers-Lalic D, Hackenberg M, Bijnsdorp IV, van Eijndhoven MA, Sadek P, Sie D, Zini N, 
Middeldorp JM, Ylstra B, de Menezes RX, Wurdinger T, Meijer GA, Pegtel DM. Nontemplated 
nucleotide additions distinguish the small RNA composition in cells from exosomes. Cell Rep. 
2014; 8:1649–1658. [PubMed: 25242326] 
232. Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a 
comprehensive review. Cancer Metastasis Rev. 2013
233. http://commonfund.nih.gov/Exrna/index
234. van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO 
Mol Med. 2014; 6:851–864. [PubMed: 24935956] 
235. Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat 
Rev Drug Discov. 2014; 13:622–638. [PubMed: 25011539] 
236. Chen Y, Gao D, Huang L. In vivo delivery of miRNAs for cancer therapy: Challenges and 
strategies. Adv Drug Deliv Rev. 2015; 81C:128–141. [PubMed: 24859533] 
237. Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet. 2012; 
3:120. [PubMed: 22783274] 
238. Montgomery RL, Yu G, Latimer PA, Stack C, Robinson K, Dalby CM, Kaminski N, van Rooij E. 
MicroRNA mimicry blocks pulmonary fibrosis. EMBO Mol Med. 2014; 6:1347–1356. [PubMed: 
25239947] 
239. Monroig PD, Chen L, Zhang S, Calin GA. Small molecule compounds targeting miRNAs for 
cancer therapy. Adv Drug Deliv Rev. 2015; 81C:104–116.
240. Xiao Z, Li CH, Chan SL, Xu F, Feng L, Wang Y, Jiang JD, Sung JJ, Cheng CH, Chen Y. A 
small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular 
carcinoma. Cancer Res. 2014; 74:6236–6247. [PubMed: 25217526] 
241. Shi Z, Zhang J, Qian X, Han L, Zhang K, Chen L, Liu J, Ren Y, Yang M, Zhang A, Pu P, Kang 
C. AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses 
epithelial-mesenchymal transition and suppresses tumor growth and progression. Cancer Res. 
2013; 73:5519–5531. [PubMed: 23811941] 
242. Shum D, Bhinder B, Radu C, Calder P, Ramirez CN, Djaballah H. An image-based biosensor 
assay strategy to screen for modulators of the microRNA 21 biogenesis pathway. Comb Chem 
High Throughput Screen. 2012; 15:529–541. [PubMed: 22540737] 
243. Connelly CM, Deiters A. Identification of Inhibitors of MicroRNA Function from Small 
Molecule Screens. Methods Mol Biol. 2014; 1095:147–156. [PubMed: 24166310] 
244. Gumireddy K, Young DD, Xiong X, Hogenesch JB, Huang Q, Deiters A. Small-molecule 
inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl. 2008; 47:7482–7484. 
[PubMed: 18712719] 
245. Young DD, Connelly CM, Grohmann C, Deiters A. Small molecule modifiers of microRNA 
miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J 
Am Chem Soc. 2010; 132:7976–7981. [PubMed: 20527935] 
246. Cai M, Yang Y. Targeted genome editing tools for disease modeling and gene therapy. Curr Gene 
Ther. 2014; 14:2–9. [PubMed: 24665839] 
247. Marraffini LA, Sontheimer EJ. CRISPR interference: RNA-directed adaptive immunity in 
bacteria and archaea. Nat Rev Genet. 2010; 11:181–190. [PubMed: 20125085] 
Hammond Page 25













248. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual- 
RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012; 337:816–821. 
[PubMed: 22745249] 
249. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. RNA-programmed genome editing in human 
cells. Elife. 2013; 2:e00471. [PubMed: 23386978] 
250. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA- 
guided human genome engineering via Cas9. Science. 2013; 339:823–826. [PubMed: 23287722] 
251. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, 
Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339:819–
823. [PubMed: 23287718] 
252. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with 
CRISPR-Cas9. Science. 2014; 346:1258096. [PubMed: 25430774] 
253. Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R, Olson EN. Prevention of 
muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science. 2014; 
345:1184–1188. [PubMed: 25123483] 
Hammond Page 26













Figure 1. The miRNA biogenesis pathway
The canonical miRNA biogenesis pathway is shown in the central part of the figure. 
miRNAs are transcribed by RNA polymerase II. The pri-miRNA transcript is cut by the 
enzyme Drosha yielding the precursor miRNA. After Dicer cleavage the mature miRNA is 
loaded into the effector complex RISC where it directs translational repression of mRNA 
targets. Two well characterized non-canonical biogenesis routes are shown in the semi-
transparent graphic. mirtrons bypass the Drosha processing step; a splicing reaction 
produces the precursor. Subsequent biogenesis steps are the same. The second non-canonical 
route shown is specific for miR-451. This miRNA precursor is directly bound and cut by 
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Argonaute 2 in a Dicer independent reaction. The remaining RNA is trimmed back to yield a 
mature miRNA.
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Figure 2. Anatomy of a miRNA poly-cistron
The miRNA cluster containing miR-106b, miR-93, and miR-25 is shown in its genomic 
context. Three miRNAs are located within an intron of the protein coding gene MCM7. 
Boxes in the MCM7 gene model represent exons, and the arrow line represents introns. 
Sequence conservation is shown. Data were adapted from the UCSC genome browser.
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Figure 3. CRISPR/Cas as a genome editing tool
The guide RNA directs the Cas9 endonuclease to target DNA. Modification of the guide 
RNA sequence allows any DNA sequence to be targeted. The only sequence requirement is 
the PAM motif NCC downstream of the target site, and a C at the 5′ end of the target site. 
The double strand break is repaired by non-homologous end joining, leading to a short 
deletion.
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